Figure 3.

Estimated relationships for PASI90, PASI100, and sPGA0/1 responses at week 16 and average risankizumab plasma concentration (C _avg) and illustration of achieving plateau of response across body weight categories with the clinical regimen in psoriasis patients. Dashed lines and shaded area: Model‐predicted probability of response, median (dashed lines) and 95% confidence interval. Gray solid symbols (median) and lines (5^th and 95^th percentiles) represents distribution of risankizumab C _avg values with phase III clinical dosing regimen of risankizumab (i.e., 150 mg SC at weeks 0 and 4 and every 12 weeks thereafter). C _avg, average plasma concentration; PASI, Psoriasis Area and Severity Index; sPGA, static Physician's Global Assessment. [Colour figure can be viewed at http://wileyonlinelibrary.com]